hOMSC300
/ Cytora
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 29, 2025
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
(clinicaltrials.gov)
- P1 | N=10 | Active, not recruiting | Sponsor: Cytora Ltd. | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1 | N=18 ➔ 10
Enrollment change • Enrollment closed • Phase classification • CNS Disorders • Movement Disorders • Multiple System Atrophy
January 26, 2023
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA
(clinicaltrials.gov)
- P1/2 | N=18 | Recruiting | Sponsor: Cytora Ltd.
New P1/2 trial • CNS Disorders • Movement Disorders • Multiple System Atrophy
1 to 2
Of
2
Go to page
1